Join Innate Pharma for an in-person investor and analyst event to discuss lacutamab, a Phase 3 ready asset.

The program will feature clinical perspectives from the Phase 2 TELLOMAK trial, presented by Pierluigi Porcu, M.D., a world expert in T-cell lymphomas. Innate Pharma’s management will provide updates on the planned Phase 3 trial and the regulatory pathway in CTCL, and, together with industry specialists, will outline the commercial opportunity for lacutamab.

The event will feature live Q&A opportunities.